High-risk anaemic Jehovah's Witness patients should be managed in the intensive care unit.
作者信息
Beliaev Andrei M
出版信息
Blood Transfus. 2013 Jul;11(3):330-2. doi: 10.2450/2013.0043-13. Epub 2013 Mar 19.
Abstract
摘要
相似文献
1
High-risk anaemic Jehovah's Witness patients should be managed in the intensive care unit.高危贫血的耶和华见证会患者应在重症监护病房进行管理。
Blood Transfus. 2013 Jul;11(3):330-2. doi: 10.2450/2013.0043-13. Epub 2013 Mar 19.
2
Supportive treatment of severe anaemia in a Jehovah's Witness with severe trauma.对一名遭受严重创伤的耶和华见证会信徒的严重贫血进行支持性治疗。
Blood Transfus. 2013 Jul;11(3):452-3. doi: 10.2450/2013.0263-12. Epub 2013 Mar 19.
3
Intravenous iron administration together with parenteral nutrition to very preterm Jehovah's Witness twins.给极低出生体重的耶和华见证会双胞胎静脉注射铁剂并同时给予肠外营养。
BMJ Case Rep. 2014 Jun 2;2014:bcr2013202167. doi: 10.1136/bcr-2013-202167.
4
Mortality risk stratification in severely anaemic Jehovah's Witness patients.严重贫血的耶和华见证人患者的死亡风险分层。
Intern Med J. 2012 Mar;42(3):e1-3. doi: 10.1111/j.1445-5994.2011.02699.x.
5
The contemporary approach to the care of Jehovah's witnesses.耶和华见证人的当代护理方法。
J Trauma. 2008 Jul;65(1):237-47. doi: 10.1097/TA.0b013e318176cc66.
6
Low-dose erythropoietin treatment is not associated with clinical benefits in severely anaemic Jehovah's Witnesses: a plea for a change.小剂量促红细胞生成素治疗对严重贫血的耶和华见证人无效：呼吁改变。
Blood Transfus. 2018 Jan;16(1):53-62. doi: 10.2450/2016.0085-16. Epub 2016 Nov 15.
7
Unusual impalement injury in a Jehovah's Witness.
J Thorac Cardiovasc Surg. 2005 May;129(5):1179-80. doi: 10.1016/j.jtcvs.2004.09.022.
8
Managing severe anemia when the patient is a Jehovah's Witness.当患者是耶和华见证会成员时，处理严重贫血的情况。
JAAPA. 2013 Apr;26(4):24, 27-9. doi: 10.1097/01720610-201304000-00006.
9
Treatment monitoring and mortality risk adjustment in anaemic Jehovah's Witnesses.贫血的耶和华见证人的治疗监测与死亡风险调整
ANZ J Surg. 2013 Mar;83(3):161-4. doi: 10.1111/j.1445-2197.2012.06228.x. Epub 2012 Sep 17.
10
Use of desmopressin and erythropoietin in an anaemic Jehovah's Witness patient with severely impaired coagulation capacity undergoing stentless aortic valve replacement.去氨加压素和促红细胞生成素在一名患有严重凝血功能障碍的贫血耶和华见证会患者接受无支架主动脉瓣置换术中的应用。
Perfusion. 2001 Nov;16(6):485-9. doi: 10.1177/026765910101600608.
引用本文的文献
1
Cost-equivalence and Pluralism in Publicly-funded Health-care Systems.公共资助医疗保健系统中的成本等效性与多元主义
Health Care Anal. 2018 Dec;26(4):287-309. doi: 10.1007/s10728-016-0337-z.
2
Hemoglobin-Based Oxygen Carrier for Traumatic Hemorrhagic Shock Treatment in a Jehovah's Witness.基于血红蛋白的氧载体用于耶和华见证会信徒创伤性失血性休克的治疗
Arch Trauma Res. 2016 Feb 2;5(2):e30610. doi: 10.5812/atr.30610. eCollection 2016 Jun.
3
Successful Treatment of Severe Anemia using Erythropoietin in a Jehovah Witness with Non-Hodgkin Lymphoma.使用促红细胞生成素成功治疗一名患有非霍奇金淋巴瘤的耶和华见证会信徒的严重贫血症
Hematol Rep. 2014 Dec 4;6(4):5600. doi: 10.4081/hr.2014.5600. eCollection 2014 Nov 19.
本文引用的文献
1
Supportive treatment of severe anaemia in a Jehovah's Witness with severe trauma.对一名遭受严重创伤的耶和华见证会信徒的严重贫血进行支持性治疗。
Blood Transfus. 2013 Jul;11(3):452-3. doi: 10.2450/2013.0263-12. Epub 2013 Mar 19.
2
Treatment monitoring and mortality risk adjustment in anaemic Jehovah's Witnesses.贫血的耶和华见证人的治疗监测与死亡风险调整
ANZ J Surg. 2013 Mar;83(3):161-4. doi: 10.1111/j.1445-2197.2012.06228.x. Epub 2012 Sep 17.
3
Mortality risk stratification in severely anaemic Jehovah's Witness patients.严重贫血的耶和华见证人患者的死亡风险分层。
Intern Med J. 2012 Mar;42(3):e1-3. doi: 10.1111/j.1445-5994.2011.02699.x.
4
Clinical benefits and cost-effectiveness of allogeneic red-blood-cell transfusion in severe symptomatic anaemia.异体输血治疗严重症状性贫血的临床获益和成本效益。
Vox Sang. 2012 Jul;103(1):18-24. doi: 10.1111/j.1423-0410.2011.01573.x. Epub 2011 Dec 13.
5
Preoperative methods to improve erythropoiesis.术前改善红细胞生成的方法。
Transplant Proc. 2011 Jan-Feb;43(1):324-6. doi: 10.1016/j.transproceed.2010.09.097.
6
Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial.接受α-促红细胞生成素治疗的透析患者运动耐量和身体功能得到改善：加拿大促红细胞生成素研究组试验的新分析。
Hemodial Int. 2011 Jan;15(1):87-94. doi: 10.1111/j.1542-4758.2010.00508.x. Epub 2010 Dec 7.
7
Erythropoietin in neonatal brain protection: the past, the present and the future.促红细胞生成素在新生儿脑保护中的作用：过去、现在与未来
Brain Dev. 2011 Sep;33(8):632-43. doi: 10.1016/j.braindev.2010.10.014. Epub 2010 Nov 24.
8
Outcomes with the use of recombinant human erythropoietin in critically ill burn patients.
Am Surg. 2010 Sep;76(9):951-6.
9
Gynecologic surgery and the management of hemorrhage.妇科手术与出血处理。
Obstet Gynecol Clin North Am. 2010 Sep;37(3):427-36. doi: 10.1016/j.ogc.2010.05.003.
10
Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.达贝泊汀α 300 或 500μg，每 3 周 1 次，联合或不联合静脉铁剂，用于化疗引起的贫血患者。
Am J Hematol. 2010 Sep;85(9):655-63. doi: 10.1002/ajh.21779.
Zotero 插件